These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 11036236)

  • 1. A new long acting ophthalmic formulation of carteolol containing alginic acid.
    Séchoy O; Tissié G; Sébastian C; Maurin F; Driot JY; Trinquand C
    Int J Pharm; 2000 Oct; 207(1-2):109-16. PubMed ID: 11036236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alginic acid effect on carteolol ocular pharmacokinetics in the pigmented rabbit.
    Tissié G; Sébastian C; Elena PP; Driot JY; Trinquand C
    J Ocul Pharmacol Ther; 2002 Feb; 18(1):65-73. PubMed ID: 11858616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a long-acting ophthalmic formulation of carteolol containing alginic acid on the corneal epithelial barrier function and water retentive effect.
    Tokuda N; Inoue J; Yamazaki I; Ueno S; Fujisawa S
    J Ocul Pharmacol Ther; 2012 Apr; 28(2):123-8. PubMed ID: 22217390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocular hypotensive efficacy and safety of once daily carteolol alginate.
    Demailly P; Allaire C; Trinquand C;
    Br J Ophthalmol; 2001 Aug; 85(8):921-4. PubMed ID: 11466245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Environmentally responsive ophthalmic gel formulation of carteolol hydrochloride.
    El-Kamel A; Al-Dosari H; Al-Jenoobi F
    Drug Deliv; 2006; 13(1):55-9. PubMed ID: 16401594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study].
    Trinquand C; Romanet JP; Nordmann JP; Allaire C;
    J Fr Ophtalmol; 2003 Feb; 26(2):131-6. PubMed ID: 12660585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Long-acting carteolol hydrochloride 2% ophthalmic solution phase IV study--investigation of the effectiveness, safety and plasma concentration].
    Kawase K; Yamamoto T; Muramatsu T; Ono J; Nakajima T; Matsuhisa A; Sugiura T; Migita M; Ishikawa Y
    Nippon Ganka Gakkai Zasshi; 2010 Nov; 114(11):976-82. PubMed ID: 21141077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Ocular hypotensive effect of 1% carteolol long-acting eye drops--a double-masked, randomized phase III study in ocular hypertension or primary open-angle glaucoma patients comparing long-acting carteolol eye drops vs. current product].
    Yamamoto T;
    Nippon Ganka Gakkai Zasshi; 2007 Jun; 111(6):463-72. PubMed ID: 17601060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly(epsilon-caprolactone) nanocapsules in carteolol ophthalmic delivery.
    Marchal-Heussler L; Sirbat D; Hoffman M; Maincent P
    Pharm Res; 1993 Mar; 10(3):386-90. PubMed ID: 8464811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and pharmacodynamic differences between ocular and nasal instillation of carteolol on intraocular pressure and heart rate in Japanese men with high CYP2D6 activity.
    Ishii Y; Nakamura K; Matsuki S; Uemura N; Muraguchi R; Nakagawa M; Nakano S; Nakatsuka K
    J Clin Pharmacol; 2002 Sep; 42(9):1020-6. PubMed ID: 12211218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of carteolol plasmatic levels after repeated instillations of long-acting and regular formulations of carteolol 2% in glaucoma patients.
    Renard P; Kovalski JL; Cochereau I; Jaulerry S; Williamson W; Elena PP; Lablache Combier M; Allaire C; Siou-Mermet R
    Graefes Arch Clin Exp Ophthalmol; 2005 Dec; 243(12):1221-7. PubMed ID: 16003515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of topical beta-blockers on tissue blood flow in the human optic nerve head.
    Tamaki Y; Araie M; Tomita K; Nagahara M; Tomidokoro A
    Curr Eye Res; 1997 Nov; 16(11):1102-10. PubMed ID: 9395769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of topical carteolol on iridial circulation in pigmented rabbit eyes.
    Tomidokoro A; Tamaki Y; Araie M; Tomita K; Muta K
    Jpn J Ophthalmol; 1998; 42(3):180-5. PubMed ID: 9690895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, Controlled, Phase 3 Trials of Carteolol/Latanoprost Fixed Combination in Primary Open-Angle Glaucoma or Ocular Hypertension.
    Yamamoto T; Ikegami T; Ishikawa Y; Kikuchi S;
    Am J Ophthalmol; 2016 Nov; 171():35-46. PubMed ID: 27565224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of pilocarpine in new ophthalmic formulations on intraocular pressure in rabbits with ocular hypertension].
    Xu Y; Chen Z; Song J
    Zhonghua Yan Ke Za Zhi; 2002 Dec; 38(12):721-4. PubMed ID: 12654220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A long acting ophthalmic gel formulations of atenolol.
    Hassan MA
    Drug Dev Ind Pharm; 2007 Nov; 33(11):1192-8. PubMed ID: 18058315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocular hypotensive effect of 8-hydroxycarteolol, a metabolite of carteolol.
    Sugiyama K; Enya T; Kitazawa Y
    Int Ophthalmol; 1989 Jan; 13(1-2):85-9. PubMed ID: 2744958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The effect of carteolol. Prolonged and increased effect by liposome suspension].
    Weber U; Michaelis L
    Ophthalmologe; 1992 Dec; 89(6):449-51. PubMed ID: 1486258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of topical 8-hydroxy carteolol on intraocular pressure and melanin granules].
    Hirota A; Mishima H; Kiuchi Y; Nagata A; Kurokawa T; Ishibashi S
    Nippon Ganka Gakkai Zasshi; 1991 Aug; 95(8):752-7. PubMed ID: 1950831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers.
    Baudouin C; de Lunardo C
    Br J Ophthalmol; 1998 Jan; 82(1):39-42. PubMed ID: 9536878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.